2024
Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment
Orive D, Echepare M, Bernasconi-Bisio F, Sanmamed M, Pineda-Lucena A, de la Calle-Arroyo C, Detterbeck F, Hung R, Johansson M, Robbins H, Seijo L, Montuenga L, Valencia K. Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment. Archivos De Bronconeumología 2024, 60: s67-s76. PMID: 39079848, DOI: 10.1016/j.arbres.2024.07.007.Peer-Reviewed Original ResearchLung cancer screeningLung cancerCancer screeningManagement of lung cancerLDCT-based lung cancer screeningSurgically resected tumorsPresence of metastasesEarly lung cancerCancer-related deathsLung cancer patientsContext of lung cancer screeningDiagnosis to earlier stagesProtein biomarkersResected tumorProtein-based biomarkersTherapeutic optionsAdjuvant strategiesLate diagnosisCancer patientsRecommended management strategiesEarly managementLung cancer detectionRobust biomarkersBenefit patientsCancerUp-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
Zhang T, Yu W, Cheng X, Yeung J, Ahumada V, Norris P, Pearson M, Yang X, van Deursen W, Halcovich C, Nassar A, Vesely M, Zhang Y, Zhang J, Ji L, Flies D, Liu L, Langermann S, LaRochelle W, Humphrey R, Zhao D, Zhang Q, Zhang J, Gu R, Schalper K, Sanmamed M, Chen L. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity. Science Immunology 2024, 9: eadh2334. PMID: 38669316, DOI: 10.1126/sciimmunol.adh2334.Peer-Reviewed Original ResearchConceptsT cell infiltrationT cell exclusionT cellsResistance to anti-PD-1 immunotherapyPoor T-cell infiltrationAnti-PD-1 immunotherapyImmunogenic mouse tumorsT cell mobilizationHuman cancer tissuesTherapeutic immunotherapyCancer immunotherapyMouse tumorsChemokine systemImmunotherapyTumor tissuesImpaired infiltrationTumorLipid metabolitesHuman cancersCancer tissuesInfiltrationA2 groupCancerPLA2G10Up-regulated
2023
516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
Cappuzzo F, Garcia V, Ou S, Brandão M, Sanmamed M, Helissey C, Wislez M, Call J, Grisanti S, Johnson M, Boni V, Jamme P, Monnet I, Siena S, Yan C, Barasa B, Richard B, Joe A, Laus G, Felip E. 516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC). Annals Of Oncology 2023, 34: s1671. DOI: 10.1016/j.annonc.2023.10.595.Peer-Reviewed Original Research